Azilsartan hair loss is best approached with timeline logic, because most medication-linked shedding behaves like telogen effluvium (TE): the trigger happens first, and increased shedding becomes noticeable later. For azilsartan, an angiotensin receptor blocker (ARB) sold as Edarbi, the practical question is a little different from drugs like losartan, valsartan, or olmesartan. In the current EDARBI monotherapy labeling, the most common adverse reaction in adults is diarrhea, and the overall adverse-event rate is described as similar to placebo. The same labeling lists other plausible treatment-related reactions such as nausea, fatigue, muscle spasm, dizziness, and cough, while postmarketing skin reactions include rash, pruritus, and angioedema—not a clear alopecia signal. That means the practical interpretation of suspected shedding on azilsartan depends even more on timing + pattern + overlap triggers, rather than on a strong molecule-level alopecia label signal.
Medical note: This article is for general education and does not provide personal medical advice. Do not stop or change azilsartan without clinician guidance. If you are not sure whether you are seeing shedding or breakage, start here: Shedding vs Breakage. If the diagnosis is unclear, start here: How Hair Loss Is Diagnosed. If you have scalp pain/burning, pustules/crusting, heavy scale, open sores, facial swelling, or rapid worsening, start here: When to See a Doctor.
Quick navigation
- Key takeaways
- What the product information says / what it doesn’t
- Timeline: onset, peak, recovery
- Pattern clues: TE vs AGA vs AA vs breakage
- When labs matter
- What to do
- When to see a doctor
- FAQ
- References
Key takeaways
- The current azilsartan monotherapy label does not clearly show a strong alopecia signal: the most common adverse reaction in adults was diarrhea (2%).
- Overall tolerability was similar to placebo: withdrawal due to adverse events was 2.4% for placebo, 2.2% for Edarbi 40 mg, and 2.7% for Edarbi 80 mg.
- Other plausible treatment-related reactions were reported: nausea, asthenia, fatigue, muscle spasm, dizziness, dizziness postural, and cough.
- Postmarketing skin reactions are listed: rash, pruritus, and angioedema, which matter clinically but are not the same as a clear alopecia signal.
- TE timing still matters: if shedding is medication-related, it is often noticed about 2–4 months after a trigger and may become obvious around 3 months after a trigger.
- Pattern matters: medication-linked TE is usually diffuse and non-scarring, not a single smooth bald patch.
- Do not self-stop: if timing fits, the next step is clinician-guided risk/benefit review, not abrupt discontinuation.
- Related on this site: ARB Hair Loss: Risk & Timeline • Losartan Hair Loss: Risk, Timeline & Fixes • Valsartan Hair Loss: Risk, Timeline & Fixes • Olmesartan Hair Loss: Risk, Timeline & Fixes • Telmisartan Hair Loss: Risk, Timeline & Fixes • Candesartan Hair Loss: Risk, Timeline & Fixes • Medication-Related Shedding • Telogen Effluvium.
What the product information says / what it doesn’t
What the current label does say: current EDARBI labeling describes azilsartan as generally well tolerated in placebo-controlled studies, with an overall incidence of adverse reactions similar to placebo. The most common adverse reaction in adults was diarrhea.
What else showed up in controlled trials: other adverse reactions with a plausible relationship to treatment and an incidence of at least 0.3% and greater than placebo included nausea, asthenia, fatigue, muscle spasm, dizziness, dizziness postural, and cough.
What it does not clearly show: in the current monotherapy labeling reviewed for this article, alopecia is not clearly listed as a common trial-table event or as a strong molecule-level signal the way it is for some other ARBs on this site.
What is still relevant: the same labeling includes postmarketing skin findings such as rash, pruritus, and angioedema. These matter clinically, but they are not the same as proving medication-triggered hair shedding.
Practical interpretation: if someone develops diffuse shedding while taking azilsartan, the useful next step is not to assume causation from the drug name alone. The real question is whether the timeline fits TE, whether the pattern is diffuse, and whether there were other triggers in the same 2–4 month window.
Timeline: onset, peak, recovery
For most practical suspected medication-shedding cases, the most useful model is telogen effluvium.
- Onset: the key clue is delay. Hair fall is often noticed about 2–4 months after a trigger and can occur around 3 months after a trigger.
- Peak: once shedding starts, it may feel worst for several weeks.
- Recovery: once the trigger is addressed or stabilizes, shedding usually slows first; visible density recovery takes longer.
- Duration clue: acute TE shedding often lasts about 3–6 months, but cosmetic regrowth usually takes longer.
This delay is why people often miss the connection. Someone may start azilsartan, feel stable for weeks, and only later notice more hair in the shower, on the pillow, or on the brush. That pattern is much more consistent with hair-cycle timing than with a dramatic same-week reaction.
Pattern clues: TE vs AGA vs AA vs breakage
Most consistent with TE
Medication-linked TE usually looks like diffuse shedding with a generally normal-looking scalp. You notice more hair fall all over, not one sharply defined bald patch.
TE + androgenetic alopecia overlap
If shedding improves but the part line keeps widening or the crown continues to thin, think about overlap with telogen effluvium vs androgenetic alopecia.
Alopecia areata is a different pattern
If you have patchy, smooth, well-defined bald areas, that is less typical for medication-triggered TE and should raise the question of alopecia areata.
Breakage is not the same as shedding
If you mostly see short snapped hairs, rough texture, or frayed ends, that points more toward hair breakage than true root-level shedding.
If the scalp is inflamed, think broader than TE
TE is usually a non-scarring diffuse shedding pattern without obvious inflammation. If the scalp is very itchy, red, painful, crusted, or visibly irritated, a simple TE explanation becomes less complete and you should review for another scalp disorder, another drug reaction, or a different diagnosis.
When labs matter
Not every patient with a plausible medication timeline needs a broad lab panel. But labs matter more when shedding is heavy, persistent, recurrent, or the history suggests overlap causes such as iron deficiency, thyroid disease, major weight change, illness, dietary restriction, or another systemic stressor in the same window.
For the site workup roadmap, use: Blood Tests & Workup.
What to do (practical plan)
- Build the timeline: write down the azilsartan start date, any dose changes, and the month shedding became noticeable.
- Confirm the pattern: diffuse shedding vs breakage vs overlap pattern hair loss vs patchy loss.
- Review stacked triggers: illness, fever, surgery, postpartum timing, dieting, weight loss, thyroid issues, low iron, or major stress in the same 2–4 month window.
- Review the exact formulation: azilsartan alone vs combination treatment, because combination products can complicate attribution.
- Talk to the prescriber: if timing fits, discuss cardiovascular risk/benefit and whether any alternative is reasonable. Do not self-stop.
- Avoid supplement roulette: add supplements only when history, labs, or clinician guidance supports a deficiency.
- Track monthly: use photos every 4 weeks in the same lighting and angle so you can judge trend, not day-to-day anxiety.
When to see a doctor
- Scalp pain, burning, pustules, open sores, or heavy scale/crusting
- Patchy smooth bald spots rather than diffuse shedding
- Obvious eyebrow or eyelash involvement
- Facial swelling or other possible medication-reaction symptoms
- Shedding that persists beyond about 6 months or returns in repeated waves
- Unclear diagnosis or rapid worsening
Start here: When to See a Doctor.
FAQ
Does the current azilsartan label clearly list alopecia?
Not clearly in the monotherapy labeling reviewed for this page. The strongest direct label points were diarrhea as the most common adverse reaction and postmarketing skin reactions such as rash and pruritus.
Does that mean azilsartan cannot be related to shedding?
No. It means the current direct label support is weaker than for some other ARBs. Individual evaluation still depends on timing, pattern, and whether there were other triggers in the same window.
Why does shedding start months later?
Because TE is delayed. The trigger shifts more hairs into the resting phase first, and the increased shedding becomes noticeable later.
Is azilsartan hair loss permanent?
When the pattern behaves like telogen effluvium, it is usually non-scarring and reversible once the trigger stabilizes, but regrowth takes time.
Should I stop azilsartan if I suspect shedding?
No. Do not stop it on your own. The safer next step is to review the timeline and treatment context with the prescriber first.
References (trusted sources)
- DailyMed: EDARBI (azilsartan kamedoxomil) — clinical-trial adverse events and postmarketing skin reactions
- DermNet: Telogen effluvium — increased hair fall is often noticed 2 to 4 months after the triggering event
- British Association of Dermatologists: Telogen effluvium — can occur around 3 months after a trigger; shedding phase usually lasts 3 to 6 months
- DermNet: Alopecia from drugs — medication-related alopecia commonly behaves like telogen effluvium
- NCBI Bookshelf (StatPearls): Telogen Effluvium
Last updated: March 13, 2026.
